Success Metrics

Clinical Success Rate
75.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
1(10%)
Results Posted
0%(0 trials)
Terminated
1(10%)

Phase Distribution

Ph phase_1
5
50%
Ph phase_3
3
30%
Ph phase_2
1
10%
Ph phase_4
1
10%

Phase Distribution

5

Early Stage

1

Mid Stage

4

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
5(50.0%)
Phase 2Efficacy & side effects
1(10.0%)
Phase 3Large-scale testing
3(30.0%)
Phase 4Post-market surveillance
1(10.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

60.0%

3 of 5 finished

Non-Completion Rate

40.0%

2 ended early

Currently Active

1

trials recruiting

Total Trials

10

all time

Status Distribution
Active(1)
Completed(3)
Terminated(2)
Other(4)

Detailed Status

unknown4
Completed3
Active, not recruiting1
Terminated1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
1
Success Rate
75.0%
Most Advanced
Phase 4

Trials by Phase

Phase 15 (50.0%)
Phase 21 (10.0%)
Phase 33 (30.0%)
Phase 41 (10.0%)

Trials by Status

active_not_recruiting110%
terminated110%
withdrawn110%
completed330%
unknown440%

Recent Activity

1 active trials
Showing 5 of 10
terminatedphase_2

Denosumab in Combination With Enzalutamide in Progressive Metastatic Castrate-resistant Prostate Cancer and Bone Metastases.

NCT03869762
active_not_recruitingphase_4

Study of XGEVA® (Denosumab) in Chinese Adults and Skeletally Mature Adolescents With Giant Cell Tumor of the Bone

NCT04586660
withdrawnphase_1

Study of CMAB807X Pre- and Post-change in Manufacturing Site and Xgeva® in Healthy Volunteers

NCT05808673
unknownphase_1

Comparing of the PK, PD, Safety and Immunogenicity of HS-20090 and Xgeva® in Healthy Adults

NCT05777109
completedphase_3

Efficacy and Safety of MW032 and Xgeva® in Subjects With Bone Metastases From Solid Tumors

NCT04812509
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT03869762Phase 2

Denosumab in Combination With Enzalutamide in Progressive Metastatic Castrate-resistant Prostate Cancer and Bone Metastases.

Terminated
NCT04586660Phase 4

Study of XGEVA® (Denosumab) in Chinese Adults and Skeletally Mature Adolescents With Giant Cell Tumor of the Bone

Active Not Recruiting
NCT05808673Phase 1

Study of CMAB807X Pre- and Post-change in Manufacturing Site and Xgeva® in Healthy Volunteers

Withdrawn
NCT05777109Phase 1

Comparing of the PK, PD, Safety and Immunogenicity of HS-20090 and Xgeva® in Healthy Adults

Unknown
NCT04812509Phase 3

Efficacy and Safety of MW032 and Xgeva® in Subjects With Bone Metastases From Solid Tumors

Completed
NCT04859569Phase 3

Efficacy and Safety of LY01011 and Xgeva® in Patients With Bone Metastases From Solid Tumors

Unknown
NCT04798326Phase 1

Comparing of the Pharmacokinetic, Pharmacodynamic, Safety and Immunogenicity of MW032 and Xgeva® in Healthy Adults

Completed
NCT04550949Phase 3

To Evaluate the Efficacy and Safety of QL1206 and Xgeva in Patients With Bone Metastases From Solid Tumors

Unknown
NCT04494373Phase 1

Comparing of the Pharmacokinetic, Pharmacodynamic, Safety and Immunogenicity of HS-20090 and Xgeva® in Healthy Adults

Unknown
NCT03651947Phase 1

Comparing of the Pharmacokinetic, Safety and Pharmacodynamic of QL1206 and Xgeva® in Healthy Adults

Completed

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10